• News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PNVL3.SA
Share

Dimed S.A. Distribuidora de Medicamentos Stocks

R$ 12.07Last Updated 15.05.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

R$ 356.40M

R$ 12.07
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumeries, personal care and beauty products, cosmetics, and dermocosmetics in Brazil. It operates in Retail and Wholesale segments. The company offers products through distribution centers in the states of Rio Grande do Sul, Paraná, and Espírito Santo. It operates 517 stores in Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo. The company was formerly known as Panvel S.A. Drogarias e Farmacias and changed its name to Dimed S.A. Distribuidora de Medicamentos in April 2000. The company is headquartered in Eldorado do Sul, Brazil.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PNVL3.SA is 18 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.05.2026 09:50

"The clock is ticking": oil hits Ma record after Trump ultimatum and nuclear power plant attack

17.05.2026 21:00

SpaceX's listing date and rival Nvidia's record: what's important about the IPO by Ma. 17

17.05.2026 18:01

Downgrade game-1789: how a relocant from Geneva made money before the French Revolution

17.05.2026 15:01

Frustration and reward: how to get rid of the tendency to over-trade

16.05.2026 17:18

Main in small-caps: BuzzFeed deal, bets on AI boom, forecast from BNP Paribas AM

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026